DICE Therapeutics, Inc. (DICE): Price and Financial Metrics
GET POWR RATINGS... FREE!
DICE Stock Price Chart Interactive Chart >
DICE Price/Volume Stats
| Current price | $31.77 | 52-week high | $45.99 |
| Prev. close | $32.12 | 52-week low | $12.64 |
| Day low | $31.43 | Volume | 241,495 |
| Day high | $32.72 | Avg. volume | 347,455 |
| 50-day MA | $32.06 | Dividend yield | N/A |
| 200-day MA | $23.67 | Market Cap | 1.51B |
DICE Therapeutics, Inc. (DICE) Company Bio
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is S011806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4Ã7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVÃ1/aVÃ6 integrin for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest DICE News From Around the Web
Below are the latest news stories about DICE THERAPEUTICS INC that investors may wish to consider to help them evaluate DICE as an investment opportunity.
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. By way of example, DICE Therapeutics... |
After Falling -4.78% During The Past Week, Should You Still Buy DICE Therapeutics Inc. (NASDAQ: DICE)?DICE Therapeutics Inc. (NASDAQ:DICE)’s traded shares stood at 0.42 million during the last session. At the close of trading, the stock’s price was $29.46, to imply a decrease of -1.73% or -$0.52 in intraday trading. The DICE share’s 52-week high remains $45.99, putting it -56.11% down since that peak but still an impressive 57.09% since … After Falling -4.78% During The Past Week, Should You Still Buy DICE Therapeutics Inc. (NASDAQ: DICE)? Read More » |
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST. |
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year. |
What Analysts Were Expecting After DICE Therapeutics Inc. (NASDAQ: DICE) rose 0.13%DICE Therapeutics Inc. (NASDAQ:DICE) shares, rose in value on Friday, 12/30/22, with the stock price up by 0.13% to the previous day’s close as strong demand from buyers drove the stock to $31.20. Actively observing the price movement in the last trading, the stock closed the session at $31.16, falling within a range of $29.58 … What Analysts Were Expecting After DICE Therapeutics Inc. (NASDAQ: DICE) rose 0.13% Read More » |
DICE Price Returns
| 1-mo | 1.83% |
| 3-mo | -7.91% |
| 6-mo | 80.82% |
| 1-year | 86.55% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.83% |
| 2022 | 23.27% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...